Pfizer commits $2.5 million annually to support Canadian researchers
MONTREAL, Oct. 22 /CNW Telbec/ - Pfizer Canada is pleased to announce the
fourth round of recipients of the Pfizer Cardiovascular Research Awards
program. The program, launched in October 2005, was developed to fund and
support cardiovascular research in Canada.
The six recipients are: Dr. Stanley Nattel, Professor of Medicine,
Montreal Heart Institute Research Center; Dr. Barbara Ballermann, Director,
Division of Nephrology and Immunology, Professor of Medicine, Faculty of
Medicine and Dentistry, University of Alberta; Dr. Richard Hoge, Assistant
Professor, Department of Physiology, Université de Montréal; Dr. Robert
Dumaine, Director and Associate Professor, Faculty of Medicine, Université de
Sherbrooke; Dr. Olivier Barbier, Assistant Professor, Faculty of Pharmacy,
Laval University; and Dr. Yan Burelle, Assistant Professor, Department of
Kinesiology, Université de Montréal.
The recipients of the awards were announced at the Canadian
Cardiovascular Congress in Quebec City this past Saturday, October 20, 2007.
The Pfizer Cardiovascular Research Awards program is designed to support
a variety of Canadian research initiatives, from traditional clinical trials
to basic research projects. All proposals are reviewed by an independent
committee of approximately 16 Canadian cardiovascular experts, chaired by Dr.
Jean-Claude Tardif, Director, Research Centre, Montreal Heart Institute,
Professor of Medicine, Université de Montréal, and recipient of the
Pfizer-Canadian Institutes of Health Research Chair of Atherosclerosis.
"As in past years, there has been an overwhelming response from medical
professionals interested in cardiovascular research," says Dr. Tardif.
"Through this important contribution, Pfizer is acting as a leader by offering
to support independent cardiovascular research in Canada. It is our hope that
these awards will help more researchers generate scientific knowledge that may
ultimately lead to an improvement of our understanding and treatment of
The Pfizer Cardiovascular Research Awards program is the most recent
initiative in the company's ongoing commitment to cardiovascular care in
Canada. Pfizer's mission is to support outstanding research with the potential
to improve the cardiovascular health and quality of life of Canadians.
The Award program is open to all researchers interested in cardiovascular
disease, including physicians, academics and pharmacists. The deadline for
submission is April 4, 2008. Additional information about the Awards program
and how to submit proposals can be found at www.PfizerCV.ca.
Last year, a new component of Pfizer's Cardiovascular Research Awards was
introduced. The Distinguished Jean Davignon Cardiovascular and Metabolic
Research Award was created to recognize the outstanding contributions Dr.
Davignon has made to research in the fields of dyslipidemia and
atherosclerosis in Canada throughout his career.
The Jean Davignon proposals will be submitted through a separate section
of the www.PfizerCV.ca Web site. All submissions will be reviewed by
Dr. Davignon and members of the same committee in charge of the Pfizer's
Cardiovascular Research Awards program.
CARDIOVASCULAR DISEASE IN CANADA
Cardiovascular disease, such as heart attack and stroke, continues to be
the leading cause of death in Canada(1). It is estimated that there are more
than 70,000 heart attacks in Canada each year(2). According to the Heart and
Stroke Foundation of Canada, 80 per cent of Canadians have one or more of the
following risk factors for cardiovascular disease - lack of physical activity,
high blood pressure, high cholesterol, diabetes and smoking - and as many as
one in ten Canadians have three of these risk factors - putting them at an
increased risk for heart attack and stroke(3).
ABOUT PFIZER CANADA INC.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, the world's
leading pharmaceutical company. Pfizer discovers, develops, manufactures and
markets prescription medicines for humans and animals. Pfizer Inc invests more
than US$7 Billion annually in R&D to discover and develop life-saving and
life-enhancing medicines. Canadian headquarters of Pfizer Global
Pharmaceuticals are in Kirkland, Quebec. For more information, visit
(1) Statistics Canada. Deaths, 2002. Available at http://statcan.ca
(2) Heart and Stroke Foundation of Canada. Heart disease. Heart Attack -
Causes & Symptoms & Statistics.
(3) Heart and Stroke Foundation. "80% of Canadians at risk - investment
in cardiovascular health essential, according to new Heart and Stroke
For further information:
For further information: or to arrange an interview with Dr. Tardif or
an award recipient: Alexandra Menear, Edelman, (514) 844-6665, ext. 226; Laura
Espinoza, Edelman, (416) 979-1120, ext. 245; Christian Marcoux, Pfizer Canada
Inc., (514) 426-6985